LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

September 3, 2019

Study Completion Date

October 27, 2019

Conditions
Appendix Cancer
Interventions
DRUG

nintedanib

Oral nintedanib, taken twice daily

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER